Clinical Scorecard: Pregnancy After CAR T Shows Early Promise
At a Glance
Category
Detail
Condition
Pregnancy after CD19-directed CAR T-cell therapy for autoimmune disease
Key Mechanisms
CD19-directed CAR T-cell therapy targets disease-associated B cells; prolonged maternal B-cell depletion may raise questions about fetal or newborn effects.
Target Population
Patients with autoimmune disease who become pregnant after CAR T-cell therapy
Care Setting
Pregnancy and postpartum follow-up after CAR T-cell treatment; evidence is from an early report of 14 pregnancies in 13 patients.
Key Highlights
The report included 14 pregnancies in 13 patients previously treated with CAR T-cell therapy for autoimmune disease.
No autoimmune disease flares were reported during pregnancy; all but one patient remained drug-free or received only prophylactic hydroxychloroquine.
Eight healthy babies had been born, five pregnancies were ongoing, and one pregnancy was electively terminated for reasons unrelated to autoimmune disease.
No CAR T cells were detected in newborns; CD19-positive B-cell counts and IgG levels were within normal ranges.
Infant follow-up ranged from 1 to 18 months, with normal development reported in all eight infants.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The researchers called for pregnancy registries to capture additional outcomes after CAR T-cell therapy.
Further studies were called for to examine the effects of lymphodepletion and CAR T-cell treatment on fertility.
Risks
The report notes questions about autoimmune disease relapse without ongoing immunosuppression and possible fetal or newborn effects of prolonged maternal B-cell depletion.
One patient developed preeclampsia with changes in proteinuria and renal-retention variables; renal biopsy showed no active lupus nephritis.
Patient & Prescribing Data
Thirteen patients with autoimmune disease: eight with systemic lupus erythematosus, two with systemic sclerosis, and one each with idiopathic inflammatory myositis, systemic sclerosis-rheumatoid arthritis overlap syndrome, or antiphospholipid syndrome.
All pregnancies occurred spontaneously. Time from CAR T-cell therapy to conception ranged from 1 to 42 months. All but one patient remained drug-free or received only prophylactic hydroxychloroquine.
Clinical Best Practices
Interpret the findings as early evidence from a small case series; the report included 14 pregnancies in 13 patients.
Consider the reported maternal and neonatal outcomes in the context of the limited follow-up, which ranged from 1 to 18 months for infants.
Support further outcome collection through pregnancy registries and research on fertility after lymphodepletion and CAR T-cell treatment.
Review identifies recurring sex-based differences across specialties, including lower use of intensive and guideline-compliant treatment among female patients.
